TransCode Therapeutics, Inc.
RNAZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $12 | $10 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $6 | $7 | $8 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $15 | $19 | $19 | $6 |
| Operating Income | -$16 | -$19 | -$19 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | $1 | $1 | -$1 |
| Pre-Tax Income | -$17 | -$19 | -$18 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$19 | -$18 | -$7 |
| % Margin | – | – | – | – |
| EPS | -47.14 | -3,453.65 | -73,187.37 | -648 |
| % Growth | 98.6% | 95.3% | -11,194.3% | – |
| EPS Diluted | -47.14 | -3,453.53 | -1,080 | -648 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $18 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$16 | -$18 | -$17 | -$7 |
| % Margin | – | – | – | – |